Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Eli Lilly Says Retatrutide Delivers Greater Weight Loss Than Ozempic in Adults With Type 2 Diabetes

Eli Lilly Says Retatrutide Delivers Greater Weight Loss Than Ozempic in Adults With Type 2 Diabetes

MT newswireMT newswire2026/10/28 14:29
10:29 AM EDT, 10/28/2026 (MT Newswires) -- Eli Lilly (LLY) said Wednesday that data from a phase 3 head-to-head trial showed that its investigational molecule retatrutide delivered greater A1C reduction and "substantially more" weight loss than Novo Nordisk's (NVO) injectable Ozempic 2mg in adults with type 2 diabetes at 80 weeks. Lilly said the trial met the primary and all key secondary endpoints, with both 9 mg and 12 mg doses of retatrutide reducing A1C by an average of 2.2% compared with 1.8% with Ozempic 2 mg at 80 weeks. Participants taking retatrutide lost an average of 44 pounds to 47 pounds, compared with 20.9 pounds with Ozempic, Lilly said. Treatment discontinuation rates due to adverse events were 4.8% and 7.9% for retatrutide 9 mg and 12 mg, versus 2.7% with Ozempic, the company said. Novo Nordisk didn't immediately respond to a request for comment by MT Newswires. Price: 1291.24, Change: +9.33, Percent Change: +0.73
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16